140 related articles for article (PubMed ID: 29858884)
1. Potential impact of introducing a nonavalent HPV vaccination.
Bogani G; Taverna F; Lombardo C; Signorelli M; Chiappa V; Casarin J; Scaffa C; Leone Roberti Maggiore U; Recalcati D; Ditto A; Martinelli F; Borghi C; Perotto S; Ferrero S; Lorusso D; Raspagliesi F
Int J Gynaecol Obstet; 2018 Sep; 142(3):338-342. PubMed ID: 29858884
[TBL] [Abstract][Full Text] [Related]
2. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily.
Capra G; Giovannelli L; Matranga D; Bellavia C; Guarneri MF; Fasciana T; Scaduto G; Firenze A; Vassiliadis A; Perino A
Hum Vaccin Immunother; 2017 Aug; 13(8):1839-1843. PubMed ID: 28594305
[TBL] [Abstract][Full Text] [Related]
3. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
4. Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
Burger EA; Portnoy A; Campos NG; Sy S; Regan C; Kim JJ
Int J Cancer; 2021 Feb; 148(4):932-940. PubMed ID: 32706907
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
6. Cervical intraepithelial neoplasia in women who had vaccination against HPV.
Bogani G; Serati M; Maggiore ULR; Ditto A; Gardella B; Ferrero S; Spinillo A; Ghezzi F; Raspagliesi F
Int J Gynaecol Obstet; 2019 Nov; 147(2):233-237. PubMed ID: 31361908
[TBL] [Abstract][Full Text] [Related]
7. Vaccination against HPV and view of new possibilities.
Mladěnka A; Sláma J
Ceska Gynekol; 2018; 83(3):218-225. PubMed ID: 30764623
[TBL] [Abstract][Full Text] [Related]
8. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
9. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule.
Brotherton JM
Aust J Gen Pract; 2018 Jul; 47(7):417-421. PubMed ID: 30114867
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg.
Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J
Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377
[TBL] [Abstract][Full Text] [Related]
13. Racial/ethnic variation in the prevalence of vaccine-related human papillomavirus genotypes.
Montealegre JR; Varier I; Bracamontes CG; Dillon LM; Guillaud M; Sikora AG; Follen M; Adler-Storthz K; Scheurer ME
Ethn Health; 2019 Oct; 24(7):804-815. PubMed ID: 28870103
[No Abstract] [Full Text] [Related]
14. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
15. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
[TBL] [Abstract][Full Text] [Related]
16. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries.
Simms KT; Smith MA; Lew JB; Kitchener HC; Castle PE; Canfell K
Int J Cancer; 2016 Dec; 139(12):2771-2780. PubMed ID: 27541596
[TBL] [Abstract][Full Text] [Related]
17. [Human papillomavirus nonavalent vaccine. Update 2017].
Bosch FX; Moreno D; Redondo E; Torné A
Semergen; 2017; 43(4):265-276. PubMed ID: 28549940
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
19. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
Carozzi F; De Marco L; Gillio-Tos A; Del Mistro A; Girlando S; Baboci L; Trevisan M; Burroni E; Grasso S; Giorgi Rossi P; Ronco G;
J Clin Virol; 2014 Jul; 60(3):257-63. PubMed ID: 24815381
[TBL] [Abstract][Full Text] [Related]
20. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
